A 32-year-old woman from Mumbai presents with 3 weeks of intermittent fever, malaise, and diarrhea. She is a chronic carrier of Salmonella typhi (positive stool culture 6 months ago). On examination, she is afebrile today, has mild hepatomegaly, and no splenomegaly. Repeat blood culture is negative, but stool culture is positive for S. typhi. What is the most appropriate management?

Explanation

## Management of Chronic Typhoid Carriage ### Clinical Context This patient is a **chronic typhoid carrier**: - Known positive stool culture >6 months ago (chronic carriage defined as >1 year, but this patient has ongoing symptomatic shedding) - Positive stool culture with negative blood culture (organism confined to biliary/intestinal reservoir) - Mild hepatomegaly suggesting biliary involvement - Intermittent symptoms consistent with ongoing carriage **Key Point:** Chronic carriers harbor *Salmonella typhi* in the gallbladder and biliary tree. They pose a significant public health risk and require active eradication therapy. ### Treatment Strategy for Chronic Carriage | Approach | Rationale | Outcome | |----------|-----------|---------| | **Ciprofloxacin 500 mg BD × 4 weeks** | Fluoroquinolone of choice; excellent biliary penetration; first-line for carriers without gallstones | ~80% eradication rate | | Cholecystectomy + antibiotics | Definitive if gallstones present; removes bacterial reservoir | >95% cure | | IV ceftriaxone + prolonged amoxicillin | No established evidence base as standard regimen; not recommended in current guidelines | Not first-line | | Observation alone | Unacceptable; ongoing public health risk | Continued shedding | **High-Yield:** Per **Harrison's Principles of Internal Medicine (21e, Ch. 159)** and **Park's Textbook of Preventive and Social Medicine**, the **first-line treatment for chronic typhoid carriers without gallstones** is **ciprofloxacin 500 mg orally twice daily for 4 weeks** (or norfloxacin 400 mg BD × 4 weeks). This achieves biliary concentrations well above the MIC for *S. typhi* and eradicates the carrier state in approximately 80% of cases. ### Why Ciprofloxacin? 1. **Excellent biliary penetration:** Fluoroquinolones achieve high concentrations in bile, targeting the gallbladder reservoir. 2. **Oral administration:** Convenient outpatient regimen; no need for hospitalization in an afebrile, stable patient. 3. **4-week duration:** Prolonged therapy is necessary to sterilize the biliary tract. 4. **Guideline-supported:** WHO and Harrison's both recommend fluoroquinolones as first-line for chronic carriers. ### Why Not the Other Options? - **Option A (Ceftriaxone IV + amoxicillin 3 months):** This combination is not a standard recommended regimen in any major guideline. IV therapy is unnecessary in an afebrile, stable carrier. - **Option B (Cholecystectomy + antibiotics):** Reserved for carriers with **documented gallstones** on imaging. The stem does not mention gallstones; surgery is not indicated without this finding. - **Option D (Observation alone):** Unacceptable. Chronic carriers are a public health hazard and must be treated and counseled on hygiene; food handlers must be removed from duty. **Clinical Pearl:** All chronic carriers should undergo **abdominal ultrasound** to detect gallstones. If gallstones are present, **cholecystectomy combined with perioperative antibiotics** is the definitive treatment (>95% cure). In the absence of gallstones, fluoroquinolone therapy for 4 weeks is the standard of care. **Mnemonic: CARRIER** — Chronic, Antibiotics (fluoroquinolone × 4 weeks), Reservoir (gallbladder), Recurrent shedding, Imaging (ultrasound for stones), Eradication (surgery if stones), Restriction (from food handling). [cite: Harrison 21e Ch. 159; Park's Textbook of Preventive and Social Medicine, 26e]